DRRD fared better in 3QFY17, beating estimates on margins by ~300bps. Revenues were in line with expectations, de-growing ~7% YoY. The margin expansion was led by improved gross margins and targeted cost cutting in SG&A expenses. The US sales continue to remain sluggish, adding only US$ 7mn over 2Q.